Canada · Delayed Price · Currency is CAD Perimeter Medical Imaging AI Earnings Call Transcripts
Fiscal Year 2026
-
A newly FDA-approved AI imaging device for breast cancer surgery is entering commercialization, targeting a large U.S. and global market with a high-margin, recurring revenue model. Expansion plans include new cancer types, international growth, and a NASDAQ listing, supported by ongoing fundraising.
Fiscal Year 2025
-
Record Q4 2025 revenue and reduced losses reflect strong S-Series adoption and cost controls. FDA PMA approval for Claire OCT sets the stage for commercial launch and broader market penetration in 2026, with new recurring revenue streams anticipated.
-
Q3 2025 saw 157% revenue growth and a 34% reduction in operating expenses, with strong S Series adoption and a pivotal B Series trial success. FDA approval for the B Series is expected in early 2026, positioning for accelerated growth and market expansion.
-
A novel imaging device using OCT and AI dramatically reduces cancer surgery re-operation rates, improving patient outcomes and lowering costs. With strong clinical results, high-margin consumables, and a unique data library, the company is poised for rapid U.S. expansion and multi-billion dollar market growth.
-
High re-operation rates in cancer surgery drive demand for real-time, high-resolution imaging solutions. The FDA-cleared S-Series device and upcoming AI-enabled B-Series have shown strong clinical and commercial traction, reducing re-operations and driving high-margin recurring revenue.
-
Q2 2025 saw 105% revenue growth and strong S-Series OCT adoption, with operating expenses down 22%. B-Series OCT pivotal trial met its endpoint and is under FDA review, with approval expected late 2025 or early 2026. Cash conservation and new leadership support continued growth.
-
High rates of repeat cancer surgeries drive significant costs and lower survival rates. A new wide-field OCT device, soon to be AI-enabled, enables real-time margin assessment, reducing reoperations and improving outcomes. FDA approval for the AI device is expected by year-end.
-
Q1 2025 revenue grew 460% year-over-year, driven by consumables, warranty programs, and the first capital sale. The B-Series pivotal trial met its endpoints, supporting an FDA PMA submission, while commercial momentum and hospital adoption continue to accelerate.
-
Achieving clean surgical margins remains a major challenge, driving high costs and poor outcomes. The company’s wide-field OCT technology, now enhanced with AI, has demonstrated significant reductions in re-operation rates and is poised for broader adoption pending FDA approval.
-
Wide-field OCT and AI technology significantly reduce re-operation rates in cancer surgery, with strong clinical trial results and a high-margin consumable business model. Market expansion targets other solid tumors, and the company is well-positioned with robust IP, manufacturing, and financial planning.
Fiscal Year 2024
-
Revenue grew 303% year-over-year in Q4 2024, driven by increased S-Series installations and utilization. The pivotal trial for the AI-enabled B-Series met its primary endpoint, leading to a PMA submission to the FDA and setting the stage for a major commercial launch.
-
The pivotal trial for the B-Series OCT with ImgAssist AI 2.0 met its primary endpoint, showing a significant reduction in residual cancer during breast-conserving surgery and demonstrating superiority over standard care. A PMA submission is planned for early 2025, with FDA approval expected to enable rapid commercial adoption.
-
Q3 2024 saw stable operating expenses, a higher net loss due to non-cash items, and $208,000 in revenue. Enrollment in the pivotal B-Series AI trial was completed, with top-line results and an FDA submission expected soon, positioning the company for a major commercial inflection.
-
Q2 2024 saw revenue grow 83% year-over-year and net loss improve 35%, with accelerated S-Series OCT adoption and 1,000 patient scans achieved. The pivotal B-Series OCT trial is ahead of schedule, with top-line data expected in Q4 and FDA submission in early 2025.
-
OCT-based technology with AI integration is reducing reoperation rates and improving outcomes in oncological surgery. Strong clinical evidence, robust IP, and a high-margin recurring revenue model support expansion, with FDA approval for the next-gen B-Series targeted for late 2025.